LOS ANGELES--(BUSINESS WIRE)--April 12, 2006--Grant Life Sciences Inc.
The proposed deal would include upfront payment of $250,000 to Grant, plus ongoing royalties upon commercialization of the resulting product; also, DTL will conduct and fund all development costs, including clinical trials, associated with the commercialization of the products developed from Grant's cervical cancer diagnostic technology.
